Robert Ross
President at SURFACE ONCOLOGY, INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Obenshain | M | 51 | 8 years | |
| Peter Barrett | M | 71 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Mark Vachon | M | 65 | 10 years | |
| Paul Clancy | M | 62 | 4 years | |
| René Russo | M | 49 | 5 years | |
| Christopher Frankenfield | M | 42 | 3 years | |
| Michael Gilman | M | 69 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 8 years |
| Tomas Jan Heyman | M | 68 | 2 years | |
| Christina Rossi | F | 48 | 3 years | |
| Yuan Xu | M | 56 | 2 years | |
| Sara Bonstein | F | 43 | 3 years | |
| Daniel Curran | M | 57 | 4 years | |
| Kevin Brennan | M | 54 | - | |
| Maria Fardis | M | 56 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 3 years |
| Shannon Rourke Devens | F | - | 8 years | |
| Melanie Call | F | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Chris Klebanoff | M | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Tom Wandless | M | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Lauren Harshman | F | - | 3 years | |
| Uli Bialucha | M | - | 3 years | |
| Katarina Luptakova | M | - | 2 years | |
| Jason Gardner | M | 53 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Carolyn Ng | M | 40 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 7 years |
| Elizabeth Pingpank | F | - | 8 years | |
| Heidi Hagen | F | 55 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Matthew Norkunas | M | 46 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 1 years |
| Lisa McGrath | F | - | 7 years | |
| Robert Woodman | M | 46 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 5 years |
| Stacey J. Davis | F | - | 2 years | |
| Virginia R. Dean | F | 58 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Anders Götzsche | M | 56 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 4 years |
| Scott Coleman | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Cole | M | 51 | 8 years | |
| J. Goater | M | 48 | 6 years | |
| Dave Grayzel | M | 56 | 9 years | |
| Linda Bain | F | 53 | 3 years | |
| Daniel Lynch | M | 65 | 6 years | |
| Jessica Fees | F | 52 | 8 years | |
| Liisa I. Nogelo | F | 53 | - | |
| Paul Wotton | M | 63 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 3 years |
| Denice Torres | F | 64 | 2 years | |
| Cameron McDonough | M | 53 | 4 years | |
| James M. DeTore | M | 59 | 2 years | |
| Seth D. Lewis | M | - | - | |
| Armen Shanafelt | M | 64 | 9 years | |
| Laurie Stelzer | F | 56 | 5 years | |
| Charles Sigal | M | 72 | 5 years | |
| Manisha Pai | F | - | 2 years | |
| Eric Sullivan | M | - | 1 years | |
| Benjamin Hickey | M | 50 | 2 years | |
| Ramy Ibrahim | M | 49 | 4 years | |
| Theresa R. Boni | F | 56 | - | |
| Martin Huber | M | 64 | 3 years | |
| Michael Ross | M | 75 | 3 years | |
| Julissa Viana | F | - | - | |
| David Schenkein | M | 66 | 8 years | |
| Wendy Dixon | M | 68 | 8 years | |
| Edward C. English | M | 57 | - | |
| Robert Tepper | M | 68 | 5 years | |
| Axel Polack | M | 67 | 7 years | |
| Steven Gillis | M | 71 | 4 years | |
| Geert-Jan Mulder | M | 58 | 9 years | |
| James Mandell | M | 79 | 5 years | |
| Vito Palombella | M | 61 | 7 years | |
| Brian King | M | - | 1 years | |
| Alison Finger | F | 60 | 6 years | |
| Chandra Adams | F | - | 2 years | |
| Salvatore Giovine | M | 41 | 1 years | |
| Peter Olagunju | M | - | 5 years | |
| Andrew Scharenberg | M | - | 3 years | |
| Sachiyo Minegishi | F | 46 | 4 years | |
| Philip Gregory | M | 53 | 6 years | |
| Wendy Dwyer | F | 50 | - | |
| David Konciak | M | - | 2 years | |
| Carsten Brunn | M | 53 | 1 years | |
| Alison O'Neill | M | 63 | 5 years | |
| Mark Angelino | M | 51 | 4 years | |
| Timothy D. Hunt | M | - | 1 years | |
| Catherine Stehman-Breen | M | 61 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 1 years |
| Faraz Ali | M | 51 | 5 years | |
| Sean O'Bryan | M | - | 1 years | |
| Nick Buffinger | M | - | 4 years | |
| Scott C. Chappel | M | 73 | - | |
| Richard Morgan | M | - | 5 years | |
| Ryan Daws | M | 50 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 4 years |
| Mitchell Finer | M | 65 | 5 years | |
| Henry Rath | M | 53 | 2 years | |
| Allene Diaz | F | 59 | - | |
| Kathleen Wilkinson | F | 52 | 9 years | |
| Richard E. T. Smith | M | 53 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert Ross
- Personal Network